Rotigotine

Drug Profile

Rotigotine

Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aderis Pharmaceuticals
  • Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
  • Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease; Restless legs syndrome
  • No development reported Fibromyalgia

Most Recent Events

  • 25 May 2016 Otsuka intends to launch Neupro® Patch in Japan for an additional dose of 18mg
  • 31 Mar 2016 Luye Pharma plans a phase I pharmacokinetics trial for Parkinson's disease (Early-stage disease) in USA (Transdermal) (NCT02728947)
  • 01 Dec 2015 UCB completes a phase II trial in adolescent patients with Restless legs syndrome in USA (Transdermal) (NCT01498120)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top